| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | MELT-300 (sublingually delivered formulation of midazolam and ketamine) Sedation for medical procedures | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | |
NDA Submission example | MELT-300 (sublingually delivered formulation of midazolam and ketamine) Sedation for medical procedures | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | |
NDA Submission example | MELT-300 (sublingually delivered formulation of midazolam and ketamine) Sedation for medical procedures | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Harrow, Inc.
$39.35
-1.98 (-4.79%)
D 34Pipeline Score Richly Valued Pharma · Commercial
Market Cap
1.48 B
EPS
-0.99
P/E Ratio
-
Value Trade
32.33 M
-5.31 %
Week
5.26 %
1 Month
14.52 %
3 Month
-26.22 %
6 Month
231.66 %
5 Year
281.56 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
205.40 K
52 Week Range
28.54 - 54.85
% held by Insiders
15.3 %
% held by Institutions
57.67 %
Enterprise Value
1.40 B
Total Shares
37.49 M
Short %
20.03 %
Float Shares
30.62 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Harrow, Inc.
455Total events
15Upcoming
106Tier-1 (high impact)
2009 – 2028Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Acquisition
Subscribe to view catalyst details
Event history 2
TBD
▲Full ResultsIHEEZOApprovedClinical Data
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | MELT-300 | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-31 | MELT-300 | Phase 3 data readout | Phase 3 | — | – | – | – |
2024-12-31 | MELT-300 | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
D34
Pipeline Score $42M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.0x
rNPV / MCap Top 48%
Micro Cap (rank 486 of 933)
Percentile RankHarrow, Inc. faces pipeline headwinds (34/100), with $106M risk-adjusted pipeline value, led by MELT-100 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MELT-100 Small molecule | Healthy Volunteers | Phase 1 | NCT04485702 | 15% | $106M | COMPLETED | 17 | - | - | Aug 29, 2020 | - | Feb 23, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IHEEZO | ocular surface anesthesia | — | 2026-08-20 | 58% less discomfort; 1.44 versus 3.06 at two minutes; 1.26 versus 2.82 at one hour; 1.62 points at two minutes; 1.56 points at one hour Read More | Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Read More | |
IHEEZO | ocular surface anesthesia | — | 2026-08-20 | 58% less discomfort; 1.44 versus 3.06 at two minutes; 1.26 versus 2.82 at one hour; 1.62 points at two minutes; 1.56 points at one hour Read More | Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Read More | |
IHEEZO | ocular surface anesthesia | — | 2026-08-20 | 58% less discomfort; 1.44 versus 3.06 at two minutes; 1.26 versus 2.82 at one hour; 1.62 points at two minutes; 1.56 points at one hour Read More | Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HROW
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HROW Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HROWHarrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow announced positive results from a study on IHEEZO, an ophthalmic gel, showing it significantly reduces patient discomfort during intravitreal injections. The study demonstrated that patients reported 58% less discomfort with IHEEZO compared to a traditional anesthetic. These findings suggest that IHEEZO may enhance patient experience and confidence among retina specialists.
Read more →HROWHarrow Announces Second Quarter 2026 Financial Results
Harrow reported its financial results for the second quarter of 2026, showcasing a significant revenue increase of 60% compared to the previous quarter and an 11% rise year-over-year. The company reaffirmed its full-year revenue guidance, projecting between $350 million and $365 million, alongside an Adjusted EBITDA forecast of $80 million to $100 million.
Read more →HROWHarrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has announced the acquisition of TYRVAYA, the first FDA-approved nasal spray for dry eye disease, from Viatris. This strategic move enhances Harrow's product portfolio, allowing for a broader range of treatment options for physicians and patients. The acquisition is valued at up to $100 million and is expected to close in the second half of 2026.
Read more →HROWHarrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow (Nasdaq: HROW) will report its second quarter financial results on August 10, 2026, after market close. A conference call will be held on August 11, 2026, at 8:00 a.m. ET to discuss these results and provide a business update. The financial results will be available on their website along with a Letter to Stockholders.
Read more →HROWSamsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Samsung Bioepis and Harrow presented interim data from a post-marketing surveillance study on SB11, a biosimilar to Lucentis, at the ASRS 2026 meeting. The study demonstrated a comparable safety profile to ranibizumab and showed significant efficacy improvements in treatment-naïve patients while maintaining efficacy in those switched from other anti-VEGF treatments. The findings support the clinical use of SB11 in retinal disease management.
Read more →HROWHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow presented three studies at the ASRS 2026 Annual Meeting, highlighting the clinical evidence supporting IHEEZO and BYOOVIZ. The studies suggest IHEEZO may reduce post-procedure pain and improve patient experience. Additionally, a large-scale trial, QUELL, is underway to further evaluate IHEEZO's effectiveness. The findings reinforce Harrow's commitment to retina specialists and patient care.
Read more →HROWHarrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow has announced the commercial launch of BYOOVIZ, an FDA-approved biosimilar for treating retinal diseases. This product, developed in partnership with Samsung Bioepis, is the first ophthalmology biosimilar in the U.S. and aims to enhance treatment options for conditions like Neovascular AMD and RVO. The launch reinforces Harrow's position in the retinal biologics market, catering to the needs of retina specialists.
Read more →HROWSamsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Samsung Bioepis has announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States in collaboration with Harrow. This partnership aims to enhance the availability of the biosimilar treatment. Further details regarding the implications of this relaunch were not provided in the article.
Read more →HROW▲ +7.3%on this news
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
Harrow has re-launched VERKAZIA, a cyclosporine ophthalmic emulsion, for treating vernal keratoconjunctivitis (VKC), particularly in children. This product aims to fill a critical gap in pediatric ophthalmic care by providing a steroid-sparing option that targets the underlying inflammation of VKC. The re-launch is supported by a robust commercial strategy to enhance physician education and patient access.
Read more →HROWHarrow to Present at William Blair’s 46th Annual Growth Stock Conference
Harrow (Nasdaq: HROW) will present at William Blair's 46th Annual Growth Stock Conference on June 3, 2026, at 8:40 AM CT in Chicago. The presentation will be available via live webcast on the company's website, with a replay accessible for 90 days. Harrow specializes in ophthalmic disease management solutions.
Read more →HROWHarrow Announces First Quarter 2026 Financial Results First Quarter 2026 and Selected Highlights: VEVYE delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded d
Harrow (HROW) reported its financial results for the first quarter of 2026, highlighting a record performance for its ophthalmic product VEVYE, despite a decline in the branded dry eye market. The company achieved revenues of $44.2 million for the quarter, although this was impacted by an $8 million gross-to-net adjustment. Harrow reaffirmed its full-year revenue guidance, expecting between $350 million and $365 million. Additionally, the company noted substantial growth in unit demand for its other products, IHEEZO and TRIESENCE, and a solid cash position of $94.6 million.
Read more →HROWHarrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026
Harrow (Nasdaq: HROW) announced it will report its first quarter 2026 financial results on May 11, 2026, after market close. A conference call and webcast will follow on May 12, 2026, at 8:00 a.m. ET for discussing the results and providing updates. The company emphasizes its dedication to ophthalmic disease management.
Read more →HROWHarrow Announces the Issuance of J-Code for IOPIDINE® 1%
Harrow has announced that IOPIDINE® 1% has been assigned a permanent J-Code (J2374) by CMS, effective July 1, 2026. This designation allows for reimbursement when administered in-office, facilitating its use in glaucoma procedures. The drug is the only FDA-approved solution to prevent intraocular pressure spikes, significantly improving patient care and procedural outcomes.
Read more →HROWLogiCare3PL Selected as Distribution Partner by Harrow
LogiCare3PL has been chosen by Harrow, Inc. as a distribution partner for its ophthalmic disease management solutions, effective February 1, 2026. The partnership aims to enhance market access and ensure business continuity through efficient logistics services. LogiCare3PL's commitment to customer-centricity and rapid execution played a key role in this collaboration.
Read more →HROWHarrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Harrow announced an add-on offering of $50 million in senior unsecured notes due 2030 to support its growth initiatives. The funds will be used for general corporate purposes, including product development and strategic opportunities. The offering is targeted at qualified institutional buyers and is not registered under the Securities Act.
Read more →HROWHarrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Harrow has announced the pricing of a $50 million offering of 8.625% senior unsecured notes due 2030. The offering, which is expected to close on March 27, 2026, will support general corporate purposes, including growth initiatives and product development. The notes will be guaranteed by the company's subsidiaries and will be treated as a single series with previously issued notes.
Read more →HROWHarrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting
Harrow (Nasdaq: HROW) announced that three abstracts related to its ophthalmic products VEVYE® and ILEVRO® have been accepted for presentation at the ASCRS 2026 Annual Meeting. The research focuses on treatment options for dry eye disease and complications following cataract surgery. The meeting will take place from April 10-13, 2026, in Washington, D.C.
Read more →HROWHarrow to Present at Leerink Partner’s 2026 Global Healthcare Conference
Harrow (Nasdaq: HROW) will present at the Leerink Partner's 2026 Global Healthcare Conference on March 10, 2026, at 8:40 AM ET in Miami, Florida. The event will be webcast live, with a replay available for 90 days. Harrow specializes in ophthalmic disease management solutions, addressing various eye conditions.
Read more →HROW▼ -28%on this newsshared move
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication
Harrow has received FDA clearance for a Phase 3 clinical trial of TRIESENCE, aimed at treating ocular inflammation and pain post-cataract surgery. The study will evaluate the drug's safety and efficacy in a randomized, placebo-controlled setting with approximately 250 patients. If successful, it could expand TRIESENCE's label and enhance its use in cataract surgery, addressing compliance issues with post-operative care.
Read more →HROW▼ -28%on this newsshared move
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Harrow (Nasdaq: HROW) reported a 36% revenue increase for 2025, with a strong fourth quarter performance. CEO Mark L. Baum highlighted growth in key products and plans for expansion in 2026, including doubling sales teams. The company aims for over $250 million in quarterly revenue by the end of 2027, despite facing challenges such as regulatory risks and financial guidance clarity.
Read more →HROWHarrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026
Harrow (Nasdaq: HROW) will report its fourth quarter and year-end financial results for 2025 on March 2, 2026. The company will also host a conference call on March 3, 2026, to discuss these results and provide a business update. Investors can access the live webcast and a replay will be available for one year.
Read more →HROW▲ +6%on this newsshared move
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits
Harrow has launched PharmaPack, a new Direct-to-Prescriber cash-pay offering aimed at providing affordable access to FDA-approved ophthalmic products. This initiative is designed to simplify the prescribing process and reduce the risks associated with off-label compounded formulations. Initially available in select states, PharmaPack aims to improve patient care by offering reliable and transparent pricing.
Read more →HROW▲ +5.1%on this news
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
OSRX, Inc. has confirmed its ongoing licensing and operational status in California, ensuring continued access to compounded ophthalmic medications for local clinicians and patients. This announcement follows the forfeiture of ImprimisRx's California license, which does not affect OSRX's standing. The company emphasizes its commitment to supporting ophthalmologists and optometrists across the nation.
Read more →HROW▲ +9.7%on this newsshared move
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth
Harrow has reaffirmed its 2025 revenue guidance of $270-$280 million, highlighting continued growth through strategic expansions in its sales force and product offerings. The company is doubling its VEVYE and TRIESENCE sales forces while expanding IHEEZO into office-based settings. Additionally, Harrow's ImprimisRx has settled regulatory matters in California, allowing for a more focused operational strategy. The launch of the OneHarrow initiative aims to unify branding and enhance patient access.
Read more →HROWHarrow to Present at Two Investor Conferences in December
Harrow (Nasdaq: HROW) will participate in two investor conferences in December 2025. The first is the BTIG 5th Annual Ophthalmology Day on December 1, followed by the Piper Sandler 37th Annual Healthcare Conference on December 2. The latter will be webcast live, with a replay available for 90 days.
Read more →HROWHarrow Announces Closing of Acquisition of Melt Pharmaceuticals
Harrow announced the successful acquisition of Melt Pharmaceuticals, marking a strategic enhancement of its ophthalmic product offerings. Melt's innovative therapies, particularly MELT-300, aim to provide non-opioid sedation alternatives in various medical and outpatient procedures. The acquisition will enable Harrow to leverage Melt's drug delivery platform and patent portfolio, targeting a large market in procedural sedation. The company plans to advance MELT-300 towards FDA approval by 2028, emphasizing its commitment to improving patient outcomes and reducing opioid reliance.
Read more →HROW▲ +13.5%on this news
Harrow Announces Third Quarter 2025 Financial Results
Harrow (HROW) reported its third quarter 2025 financial results, highlighting significant progress in its portfolio, particularly with VEVYE and IHEEZO. The CEO emphasized upcoming initiatives such as the launch of TRIESENCE and the Harrow Access for All program. The company is optimistic about its growth trajectory and future performance.
Read more →HROWHarrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
Harrow (Nasdaq: HROW) will report its financial results for the third quarter of 2025 on November 10, 2025, following the market close. This announcement includes a conference call scheduled for November 11, 2025, to offer a business update. Harrow specializes in ophthalmic disease management and is focused on delivering accessible and effective medications for various ocular conditions.
Read more →HROW▼ -7.2%on this news
ImprimisRx Announces Leadership Changes
Harrow (Nasdaq: HROW) has announced significant leadership changes at its subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO, bringing over 20 years of experience in healthcare and pharmaceuticals. Bridseida Cruz joins as Head of Quality, with a strong background in compliance and operations. These appointments aim to enhance ImprimisRx's operational capabilities and align with Harrow's vision for growth in ophthalmic solutions.
Read more →HROW▼ -7.2%on this newsshared move
ImprimisRx Announces Leadership Changes Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx
Harrow, a provider of ophthalmic disease management solutions, announced key leadership changes at its subsidiary, ImprimisRx. Frank Mullery has been appointed as the new CEO, bringing over 20 years of experience in the healthcare and pharmaceutical sectors. Bridseida Cruz will serve as Head of Quality with a strong background in ensuring compliance and managing quality operations. The company's chairman expressed optimism about their potential to drive critical innovations in ophthalmic care.
Read more →HROWHarrow to Acquire Melt Pharmaceuticals
Harrow has announced its agreement to acquire Melt Pharmaceuticals, a company developing non-opioid sedation therapies. Melt's lead product, MELT-300, has shown superior efficacy in clinical trials compared to traditional sedation methods. The acquisition aims to enhance Harrow's offerings in ophthalmic disease management and address the opioid crisis. Harrow plans to submit an NDA for MELT-300 in 2027, targeting a commercial launch in 2028.
Read more →HROWHarrow Launches Harrow Access for All (HAFA)
Harrow has announced the launch of Harrow Access for All (HAFA), a program designed to enhance patient access to its ophthalmic medications. Set to be available in late 2025, HAFA expands upon the successful VEVYE Access for All initiative. The program aims to streamline prescribing and improve affordability for patients, ensuring timely access to necessary treatments.
Read more →HROW▲ +8.6%on this news
Harrow Announces Agenda and Speakers for Investor & Analyst Day
Harrow has announced its Investor & Analyst Day scheduled for September 26, 2025, in New York. The event will provide a comprehensive overview of the company's business, including its commercial portfolio and pipeline. Presentations will be made by Harrow's leadership team and physician key opinion leaders, focusing on evolving treatment paradigms and market dynamics.
Read more →HROWHarrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
Harrow has announced the pricing of its $250 million offering of senior unsecured notes due 2030, which will bear an interest rate of 8.625%. The offering is expected to close on September 12, 2025, and proceeds will be used to repay existing debts and support corporate purposes. The notes are being offered only to qualified institutional buyers and are not registered under the Securities Act.
Read more →HROW▲ +7.5%on this newsshared move
Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027
Harrow has announced a private offering of $250 million in senior unsecured notes due in 2030, along with a commitment for a $40 million revolving credit facility. The funds will be used to repay existing debts, including senior notes due in 2026 and 2027. Additionally, Harrow has issued a conditional notice for the redemption of its outstanding 2027 notes, contingent upon the completion of the offering. This move aims to enhance the company's financial flexibility and support its growth strategy in ophthalmic disease management.
Read more →HROWHarrow Announces Second-Quarter 2025 Financial Results Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period GAAP net inc
Harrow (Nasdaq: HROW) announced its financial results for the second quarter of 2025, highlighting a notable increase in total revenues to $63.7 million, reflecting a 30% growth over the same period last year. The company reported a GAAP net income of $5 million alongside an adjusted EBITDA of $17 million. Harrow's market share grew by nearly 3%, driven by significant prescription growth, particularly for its VEVYE and IHEEZO products. However, the company faces challenges, including increased current liabilities and ongoing compliance scrutiny at its outsourcing facility.
Read more →HROWHarrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
Harrow (Nasdaq: HROW) will participate in the H.C. Wainwright 5th Annual Ophthalmology Conference on August 13, 2025. CEO Mark L. Baum and CFO Andrew Boll will engage in a fireside chat and a panel discussion on novel treatments. The event will be available for live streaming and later replay on Harrow's website.
Read more →HROWHarrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
Harrow, a North American eyecare pharmaceutical company, has announced that it will report its financial results for the second quarter of 2025 on August 11, 2025. Following the report, a conference call will be held on August 12, 2025, to discuss the results and provide a business update. The company emphasizes its commitment to making ophthalmic pharmaceutical products accessible and affordable for patients. For more information, stakeholders can visit Harrow's official website.
Read more →HROWHarrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States Harrow to assume full commercial responsibility for BYOOVIZ and OPUVIZ by the end of 2025
Harrow (Nasdaq: HROW) has entered a commercialization agreement with Samsung Bioepis, acquiring U.S. commercial rights to the ophthalmology biosimilars BYOOVIZ and OPUVIZ. This strategic acquisition is expected to be completed by the end of 2025, allowing Harrow to enhance its portfolio in the retinal disease treatment market. The move is seen as a significant step in Harrow's commitment to delivering innovative and affordable eyecare solutions, as the retinal disease treatment market represents a substantial opportunity. CEO Mark L. Baum emphasized the potential for these products to improve patient access to vital therapies.
Read more →HROWHarrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan
Harrow has announced the acquisition of exclusive U.S. commercial rights for BYQLOVI, a clobetasol propionate ophthalmic suspension, from Formosa Pharmaceuticals. This product has recently received FDA approval for treating post-operative inflammation and pain following ocular surgery. BYQLOVI is being highlighted as a clinically differentiated corticosteroid with a unique nanoparticle formulation that improves dosing consistency. It is expected to be available to the U.S. market in the fourth quarter of 2025, targeting a significant market of over 7 million ophthalmic surgeries annually.
Read more →HROWHarrow Announces First-Quarter 2025 Financial Results First-Quarter 2025 and Recent Selected Highlights: Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period VEVYE revenues increased
Harrow (Nasdaq: HROW) reported a 38% increase in total revenues for the first quarter of 2025, reaching $47.8 million, attributed to strong sales, particularly of its VEVYE product. While VEVYE revenues increased 35% from the last quarter, the company still faced a GAAP net loss of $17.8 million and negative adjusted EBITDA of $2.0 million. Cash flow from operations hit a record $19.7 million and the launch of the VEVYE Access for All program is expected to boost market share further. Despite ongoing operational challenges, Harrow maintains a confident outlook for achieving its 2025 revenue target of over $280 million.
Read more →HROWHarrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results Fourth-Quarter, Full-Year 2024, and Recent Highlights: Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 Revenues of $1
Harrow announced its fourth-quarter and year-end 2024 financial results, highlighting record revenues of $66.8 million for Q4 2024, an 84% increase from Q4 2023, and total revenues of $199.6 million for the full year, up 53%. The company's adjusted EBITDA reached $22.5 million for Q4 2024, reflecting strong operational efficiency. However, the FY 2024 results showed a GAAP net loss of $(17.5) million, raising concerns about overall profitability. Future expectations are optimistic with initiatives like the VEVYE Access for All program poised to drive market share growth.
Read more →HROWHarrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance Company Expects to Provide Revised Dates for Release of Audited Financial Results, Conference Call, and L
Harrow (Nasdaq: HROW) announced its preliminary financial results for Q4 and full year 2024, projecting revenues for 2025 to exceed $280 million. The release of audited results is delayed due to additional time needed by their independent auditor. The preliminary results indicate a range of $65 - $67 million in Q4 revenues; however, Harrow reported a net loss for the year. The company emphasizes its commitment to accurate financial reporting and has met its leverage ratio terms to avoid issuing warrants to lenders.
Read more →HROW▼ -17.3%on this news
Harrow Announces Third Quarter 2024 Financial Results Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) millio
Harrow (Nasdaq: HROW) reported strong financial results for the third quarter of 2024, with revenues jumping 44% year-over-year to $49.3 million. Despite a GAAP net loss of $(4.2) million, Adjusted EBITDA remained robust at $8.8 million, suggesting effective operational performance. The company also noted a significant increase in VEVYE prescriptions and positive demand trends for its portfolio. Management anticipates a record-breaking finish for the year, bolstered by new partnerships and a strategic relaunch of TRIESENCE.
Read more →HROWHarrow Announces Second Quarter 2024 Financial Results Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash eq
Harrow Inc. announced its financial results for the second quarter of 2024, highlighting its record revenues of $48.9 million and significant operational achievements. The company reported a GAAP net loss of $(6.5) million, although its adjusted EBITDA was $8.8 million. In terms of product performance, demand for IHEEZO grew by 98% and VEVYE prescriptions surged by 212%, reflecting strong market growth. The management expressed optimism for future profitability and revenue expansion amid ongoing developments.
Read more →HROWHarrow Announces First Quarter 2024 Financial Results First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confi
Harrow (HROW) reported its financial results for the first quarter of 2024, showcasing significant growth with revenues reaching $34.6 million, a substantial increase of 33% from the prior year. The company received positive news from the Centers for Medicare & Medicaid Services regarding the reimbursement of its product IHEEZO, bolstering its market position. Despite these positives, Harrow also reported a larger net loss and increased operating expenses, raising concerns about financial management. Overall, Harrow remains optimistic about continuing its growth trajectory in the ophthalmic market throughout 2024.
Read more →HROWHarrow Announces Fourth Quarter and Year-End 2023 Financial Results Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared
Harrow (Nasdaq: HROW) reported its financial results for the fourth quarter and year-end of 2023, revealing a significant revenue increase of 47% to $130.2 million compared to 2022. Despite this growth, the company experienced a larger GAAP net loss of $(24.4 million) versus $(14.1 million) in the prior year. The Adjusted EBITDA improved dramatically, growing by 116% to $28.1 million, indicating operational efficiency. The successful launches of key products and the hiring of skilled talent position Harrow for anticipated future growth.
Read more →HROWHarrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products NASHVILLE, Tenn. and TORONTO, Ontario, Canada (
Harrow, Inc. has entered an exclusive out-licensing agreement with Apotex Inc. for five branded ophthalmic pharmaceutical products to be marketed in Canada. Apotex will handle the distribution of existing products VERKAZIA and Cationorm PLUS while seeking market approval for VEVYE, IHEEZO, and ZERVIATE. This partnership is aimed at enhancing the availability of innovative ophthalmic treatments for Canadian patients, aligning with Apotex's strategic expansion in the pharmaceutical market.
Read more →HROWHarrow Announces New Appointments to its Board of Directors
Harrow (Nasdaq: HROW) has announced the immediate appointment of Adrienne Graves, Ph.D., and Lauren Silvernail to its Board of Directors. This expansion brings the total number of board members to six, enhancing the company's leadership with experienced professionals in ophthalmology and finance. Both appointees bring extensive backgrounds from leading pharmaceutical firms and are expected to contribute to Harrow's strategic growth and stockholder value maximization efforts.
Read more →HROWMelt Pharmaceuticals Provides Corporate Update NASHVILLE, Tenn. (
Melt Pharmaceuticals, Inc. has provided a corporate update, noting that its MELT-300 product achieved the primary sedation endpoint in its Phase 2 study for cataract surgery. The FDA's recent response has paved the way for the planned Phase 3 program, expected to begin in early 2024. Additionally, Melt has completed a debt settlement with its largest shareholder, Harrow, Inc., and secured funding for the upcoming studies. The company aims to enhance patient comfort during medical procedures through its novel non-opioid sedation methods.
Read more →HROWHarrow Announces Third Quarter 2023 Financial Results Third Quarter 2023 and Recent Selected Highlights: Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase o
Harrow (HROW) reported its third quarter 2023 financial results, achieving record revenues of $34.3 million, a 50% rise from the previous year. Adjusted EBITDA saw a remarkable increase of 270%, yet the company posted a GAAP net loss of $4.4 million. Despite mixed operational performance, particularly with the launch of IHEEZO, the firm is optimistic about future growth in revenues and EBITDA for 2024, driven by strategic initiatives and adjustments made this year. Harrow has also indicated a few months' lag in revenue forecasts for certain products, but remains positive about restoring its compounding business's growth trajectory.
Read more →HROWHarrow Announces Second Quarter 2023 Financial Results Second Quarter 2023 and Recent Selected Highlights: Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase
Harrow Health, Inc. reported its financial results for the second quarter of 2023, highlighting record revenues of $33.5 million, which represents a 44% increase year-over-year. Adjusted EBITDA also surged by 144%, reaching $11.0 million. However, the company recorded a GAAP net loss of $4.2 million and saw a substantial reduction in cash reserves. Additionally, Harrow has made strategic acquisitions to bolster its product portfolio, enhancing its position in the ophthalmic pharmaceutical market.
Read more →HROW▲ +17.8%on this news
Harrow Prices $60 Million Public Offering of Common Stock
Harrow (Nasdaq: HROW) announced the pricing of an underwritten public offering of 3,380,282 shares of its common stock at a price of $17.75 per share, aiming to raise gross proceeds of $60 million. The offering is expected to close on or around July 21, 2023, contingent on customary conditions. The funds will primarily be used for an acquisition and other general corporate purposes, including future product acquisitions and working capital needs. Riley Securities is the lead manager of the offering, with additional terms set under Harrow’s existing shelf registration statement.
Read more →HROWHarrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
Harrow (Nasdaq: HROW) has announced preliminary financial guidance for the second quarter of 2023, projecting revenues in excess of $31 million, marking an improvement from $23.3 million in the previous year. Adjusted EBITDA is expected to exceed $9.3 million, indicating robust financial performance. However, the company cautions that these figures are preliminary and subject to changes following its quarter-end review process, emphasizing uncertainty in the details that could materially affect final results. Full financial results are set to be released on August 9, 2023.
Read more →HROWHarrow Announces First Quarter 2023 Financial Results First Quarter 2023 and Recent Selected Highlights: Record revenues of $26.1 million, up 18% over $22.1 million for the prior-year quarter and 28% over sequential quar
Harrow (Nasdaq: HROW) announced its first quarter 2023 financial results, revealing record revenues of $26.1 million, up 18% compared to the same period last year. The company highlighted the successful completion of New Drug Applications and the launch of its FDA-approved product, IHEEZO, at an industry conference. Despite this growth, Harrow reported a net loss of $6.6 million, indicating challenges in profitability. The company reaffirms its 2023 revenue guidance, forecasting net revenues of $135 million to $143 million.
Read more →HROWHarrow Announces New $100 Million Secured Credit Facility with Oaktree
Harrow has announced a $100 million secured credit facility with Oaktree Capital Management, aimed at enhancing its financial strength. The facility features an interest rate tied to the three-month secured overnight financing rate plus 6.50% and is set to mature in approximately three years. Proceeds will be utilized to repay existing debt and fund future milestone payments related to acquisitions. Harrow's leadership and Oaktree both express optimism about the partnership and the company's growth trajectory.
Read more →HROWHarrow Announces Fourth Quarter and Year-End 2022 Financial Results 2022 and Recent Highlights: Full-year 2022 revenues of $88.6 million, up 22% over full-year 2021 revenues of $72.5 million Sold all non-ophthalmology as
Harrow announced its financial results for Q4 and the year ended December 31, 2022, reporting a revenue increase of 22% to $88.6 million compared to 2021. The company successfully transitioned to a pure-play ophthalmic pharmaceutical firm by selling non-ophthalmic assets and acquired U.S. rights to various ophthalmic products. Additionally, the FDA approved IHEEZO, a topical ocular anesthetic, which is expected to launch in May 2023. The company has also launched several new compounded formulations aimed at improving accessibility to eye care treatments.
Read more →HROW▲ +5.2%on this news
Harrow Health, Inc.: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Harrow Health, Inc. regarding potential securities fraud. The firm's inquiry comes after allegations of undisclosed investigations by the U.S. Department of Justice and a warning letter from the FDA about misleading marketing claims. Following these revelations, Harrow's stock experienced a drop of 3.2%, significantly impacting investors. The law firm encourages affected investors to consider pursuing claims to recover their losses.
Read more →HROWHarrow Health Shareholder News: Johnson Fistel Encourages Harrow Health Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
Harrow Health, Inc. is facing a class action investigation initiated by Johnson Fistel, LLP, after allegations of securities law violations. The investigation concerns whether Harrow failed to disclose adverse information related to its product, Dexycu, including a DOJ subpoena and an FDA Warning Letter. These issues relate to the quality and marketing practices of the drug. Following the emergence of this information, Harrow's stock price dropped significantly, indicating investor concerns about potential losses.
Read more →HROWHarrow Closes Acquisition of U.S. Rights to ILEVRO , NEVANAC , VIGAMOX , MAXIDEX , and TRIESENCE and Will Begin Receiving Net Profit Payments for Acquired Products
Harrow has closed the acquisition of the U.S. rights to five ophthalmic products, including ILEVRO and VIGAMOX, for $130 million. Following a six-month transition period, Harrow will start receiving net profit payments from these products while transferring NDAs. The company anticipates that these products will contribute positively to its financial performance and has reaffirmed its revenue guidance for 2023. However, the acquisition carries significant financial commitments and exposure to market risks.
Read more →HROWHarrow Secures Capital to Close Recently Announced Acquisition Announces Pricing of $35 Million Aggregate Principal Amount Offering of 11.875% Senior Notes Due 2027
Secures Capital to Close Recently Announced Acquisition Pricing of $35 Million Aggregate Principal Amount Offering of Senior Notes Due 2027 Tenn., December 16, 2022 - Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, d
Read more →HROW▲ +15%on this newsshared move
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones
Announces Proposed Offering of $100 Million of Senior Notes Due 2027 "BB" Rating from Egan-Jones Tenn., December 14, 2022 - Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovat
Read more →HROW▲ +15%on this newsshared move
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO , NEVANAC , VIGAMOX , MAXIDEX , and
Enters into Agreement to Acquire Exclusive U.S. Rights to NEVANAC , VIGAMOX , MAXIDEX , and TRIESENCE Tenn., December 14, 2022 - Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative opht
Read more →HROWHarrow Announces Third Quarter 2022 Financial Results Selected Recent Highlights: FDA approval of IHEEZO for ocular surface anesthesia Launch of Fortisite , fortified antibiotics Launch of atropine.com compounded atropin
Announces Third Quarter 2022 Financial Results FDA approval of IHEEZO for ocular surface anesthesia Launch of Fortisite , fortified antibiotics Launch of atropine.com compounded atropine portal Revenues of $22.8 million, up 22% over $18.7 million for the prior-year quart
Read more →HROWHarrow Sells Non-Ophthalmic Compounding Business
Sells Non-Ophthalmic Compounding Business Tenn., October 5, 2022 - Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non-ophthalmi
Read more →HROW▲ +27.9%on this news· ran to +59% by day 3
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
Harrow announced FDA approval of IHEEZO™, the first U.S. approved chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia in nearly 14 years. The approval highlights its safety and efficacy, with potential significant impact on eyecare practices.
Read more →HROWHarrow Health Announces Second Quarter 2022 Financial Results Revenues Increase for Eighth Consecutive Quarter Highlights for Second Quarter 2022: Record revenues of $23.3 million, up 29% over $18.1 million for the prior
Health Announces Second Quarter 2022 Financial Results Increase for Eighth Consecutive Quarter for Second Quarter 2022: Record revenues of $23.3 million, up 29% over $18.1 million for the prior-year quarter Record gross profit of $16.8 million, up 22% over $13.7 million fo
Read more →HROWHarrow Health Announces First Quarter 2022 Financial Results Seventh Consecutive Quarter of Record Results Highlights for First Quarter 2022: Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year
Health Announces First Quarter 2022 Financial Results Consecutive Quarter of Record Results for First Quarter 2022: Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year quarter Record gross profit of $16.2 million, up 38% over $11.7 million for th
Read more →HROWHarrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021: Record revenues of $20.2 million, a 38% increase compared with $
Health Announces Fourth Quarter and Year-End 2021 Financial Results Consecutive Quarter of Record Revenues for Fourth Quarter 2021: Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prior-year quarter; Gross profit was a record $15.1 mill
Read more →HROWHarrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops Expands and Strengthens Portfolio of Product Offerings for U.S. Ophthalmic Surgical and Acute Care Markets
Health Acquires U.S. Commercial Rights to Four Branded Eye Drops and Strengthens Portfolio of Product Offerings U.S. Ophthalmic Surgical and Acute Care Markets Tenn., December 20, 2021 - Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announ
Read more →HROWEyePoint Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU - ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU and absorb the m
Pharmaceuticals and Harrow Health's ImprimisRx Announce Expanded Commercial Alliance for DEXYCU ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU and absorb the majority of EyePoint's DEXYCU commercial organization; EyePoint to retain
Read more →HROWHarrow Health Announces Third Quarter 2021 Financial Results Revenues Reach Record Levels for Fifth Consecutive Quarter Highlights for Third Quarter 2021: Record revenues of $18.7 million, a 30% increase compared with $1
Health Announces Third Quarter 2021 Financial Results Reach Record Levels for Fifth Consecutive Quarter for Third Quarter 2021: Tenn., November 9, 2021 - Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced results for the third quarte
Read more →HROWHarrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 NASHVILLE, Tenn., (
Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 Tenn., (September 2, 2021) - Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceut
Read more →HROWHarrow Health Acquires Ophthalmic Surgical Drug Candidate from Wakamoto Pharmaceutical Co., Ltd. NASHVILLE, Tenn. and TOKYO
Health Acquires Ophthalmic Surgical Drug Candidate Wakamoto Pharmaceutical Co., Ltd. Tenn. and TOKYO, August 18, 2021 - Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceuti
Read more →HROWHarrow Health Announces Second Quarter 2021 Financial Results Fourth Consecutive Quarter of Record Results Highlights for Second Quarter 2021:7 Record revenues of $18.1 million, a 125% increase compared with $8.1 million
Health Announces Second Quarter 2021 Financial Results Consecutive Quarter of Record Results for Second Quarter 2021:7 Record revenues of $18.1 million, a 125% increase compared with $8.1 million for the prior-year period; Gross margin was 75.6%, compared with 60.2% for the
Read more →HROWHarrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica New Drug Application Expected to Be Filed in Late 2021 NASHVILLE, Tenn. and
Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica Drug Application Expected to Be Filed in Late 2021 Tenn. and MENDRISIO, Switzerland, July 27, 2021 - Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it
Read more →HROWHarrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021
NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the second quarter and six months ended June 30, 2021, on Tuesday, August 10, 2021, aft
Read more →HROWSurface Ophthalmics Announces $25 Million Private Round of Fundraising Proceeds from the capital raise will help to support and advance Surface's ongoing clinical programs in ocular diseases PLEASANTON, California, 21 Ju
Ophthalmics Announces $25 Million Private Round of Fundraising from the capital raise will help to support and advance Surface's ongoing clinical programs in ocular diseases California, 21 July 2021 - Surface Ophthalmics, Inc., a pharmaceutical company focused on the developmen
Read more →HROWHarrow Health Granted Two Patents for Novel Surgical Dilation Formulation
NASHVILLE, Tenn., July 15, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) an ophthalmic-focused healthcare company, today announced that the United States Patent and Trademark Office issued two Patents, No. US 10,993,921, B2, dated May 4, 2021, and No. US 11,045,432
Read more →HROWHarrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amoun
Read more →HROWHarrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and "BB" Rating from Egan-Jones
Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 "BB" Rating from Egan-Jones Tenn., June 14, 2021 - Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced that it has commenced
Read more →HROWHarrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026
Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 Tenn., June 14, 2021 - Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced the pricing of i
Read more →HROWHarrow Health Launches New Corporate and Investor Website
NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its newly redesigned corporate and investor website, harrowinc.com. The new website,
Read more →HROWHarrow Health Announces Record First Quarter 2021 Financial Results Highlights for First Quarter 2021: Revenues of $15.4 million, a 31% increase compared with $11.8 million for prior year; Adjusted EBITDA (1) , a non-GAA
Health Announces Record First Quarter 2021 Financial Results for First Quarter 2021: Revenues of $15.4 million, a 31% increase compared with $11.8 million for prior year; Adjusted EBITDA (1) , a non-GAAP measure, reached a new high of $4.3 million, compared with $0.4 millio
Read more →HROWHarrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes
NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of an additional $5.0 million of 8.625% senior notes due 2026 (the “Additional Notes”),
Read more →HROWHarrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock
Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock NASHVILLE, Tenn., May 5, 2021 - Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced that the Company has closed on a
Read more →HROWHarrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021
NASHVILLE, Tenn., April 27, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2021, on Tuesday, May 11, 2021, after the market clo
Read more →HROWHarrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026
NASHVILLE, Tenn., April 20, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $50 million aggregate principal amou
Read more →HROWHarrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026
Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026 Tenn., April 15, 2021 - Harrow Health, Inc. (NASDAQ: HROW) ("Harrow Health" or the "Company"), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public o
Read more →HROWHarrow Health Announces Offering of $25 Million Senior Notes Due 2026 and “BB” Rating from Egan-Jones
NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced it has commenced an underwritten registered public offering of $25 million aggregate principal amount of senior notes due 2026 (the “
Read more →HROWHarrow Health Announces Preliminary First Quarter 2021 Financial Results
Harrow Health Announces Preliminary First Quarter 2021 Financial Results April 14, 2021 - Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced certain preliminary unaudited financial results for the first quarter ended March 31, 2021.
Read more →HROWHarrow UK Lasting Powers Of Attorney Agents – Consulting Services Launched
Brampton, United Kingdom, April 09, 2021 (GLOBE NEWSWIRE) -- LPA Now, a paralegal expert in Brampton, Cumbria, announced the launch of an updated range of services for clients in Harrow, London, and the surrounding area. The company has extensive experience in the guidance, advic
Read more →HROWHarrow Health Announces Fourth Quarter and Year-End 2020 Financial Results Company's Prior-Quarter Momentum Continues in Fourth Quarter Highlights for Fourth Quarter 2020: Revenues of $14.6 million, a 16% increase compar
Health Announces Fourth Quarter and Year-End 2020 Financial Results Prior-Quarter Momentum Continues in Fourth Quarter for Fourth Quarter 2020: Revenues of $14.6 million, a 16% increase compared with $12.6 million for prior year; Adjusted EBITDA reached a new high of $4.0
Read more →HROWHarrow Health to Participate in H.C. Wainwright Global Life Sciences Conference
NASHVILLE, Tenn., March 02, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the H.C. Wainwright Global Lif
Read more →HROWHarrow Health to Announce Fourth Quarter and Year-End 2020 Financial Results on March 8, 2021
NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2020, on Monday, March 8, 2021, after th
Read more →HROWMelt Pharmaceuticals Completes Phase 1 Study for Sublingual, Non-Opioid Pain and Sedation Drug Candidate Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 Boston (
Pharmaceuticals Completes Phase 1 Study Sublingual, Non-Opioid Pain and Sedation Drug Candidate Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 (February 9, 2021) - Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-cla
Read more →HROWSurface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye SURF-200 leverages the proven Klarity vehicle and betamethasone corticosteroid to treat acute dry eye PLEASANTON, Califor
Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye leverages the proven Klarity vehicle and betamethasone corticosteroid to treat acute dry eye California 4 FEBRUARY 2021 - Surface Ophthalmics, Inc., a pharmaceutical company focused on th
Read more →HROWSurface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease Innovative head-to-head study will compare SURF-100 against leading on-market competitors
Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease head-to-head study will compare SURF-100 against leading on-market competitors lifitegrast ophthalmic solution 5% and cyclosporine ophthalmic emulsion 0.05
Read more →HROWSurface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation Investigational therapy SU
Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation therapy SURF-201 met all primary endpoints for the treatment of pain and inflammation follo
Read more →HROWHarrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference
NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Confere
Read more →HROWHarrow Health Publishes Third Quarter 2020 Letter to Stockholders Nashville, TN - November 9 , 2020 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harr
Health Publishes Third Quarter 2020 Letter to Stockholders TN - November 9, 2020 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health's Letter to Stockholders for the third quarter 2020. L. Baum, CEO
Read more →HROWHarrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020
NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time /
Read more →HROWHarrow Health Appoints Larry Van Horn to its Board of Directors
NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors. Mark L. Baum, CEO of Harrow Health, commented, “I am honored to welcome Larry to the Harrow Health Board of Direct
Read more →HROWHarrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September 17, 2020, on a virtual platform. Mark L. Baum, CEO, and Andrew Boll, CFO, will
Read more →HROWHarrow Health Publishes Second Quarter 2020 Letter to Stockholders Nashville, TN
Health Publishes Second Quarter 2020 Letter to Stockholders TN - August 10, 2020 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2020. Please click here to review Harrow Health's Letter to Stockholders for the second quarter 2020. L. Baum, CE
Read more →HROWHarrow Health to Announce Second Quarter 2020 Financial Results on August 10, 2020
NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time /
Read more →HROWHarrow Health Set to Join Russell 2000 Index and Russell 3000 Index
NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective
Read more →HROWHarrow Health Publishes First Quarter 2020 Letter to Stockholders Nashville, TN
Health Publishes First Quarter 2020 Letter to Stockholders TN - May 11, 2020 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2020. Please click here to review Harrow Health's Letter to Stockholders for the first quarter 2020. L. Baum, CEO of H
Read more →HROWHarrow Health to Announce First Quarter 2020 Financial Results on May 11, 2020
NASHVILLE, Tenn., April 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, May 11, 2020, it will release first quarter 2020 financial results and host a conference call at 5:00 p.m. Eastern Daylight Time / 2:
Read more →HROWHarrow Health Appoints Teresa Sparks to its Board of Directors
NASHVILLE, Tenn., March 17, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors. Mark L. Baum, CEO of Harrow Health, commented, “I am honored to welcome Teresa to the Harrow Health Board of Direct
Read more →HROWHarrow Health Publishes Fourth Quarter 2019 Letter to Stockholders Nashville, TN
Health Publishes Fourth Quarter 2019 Letter to Stockholders TN - March 13, 2020 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2019. Please click here to review Harrow Health's Letter to Stockholders for the fourth quarter 2019. L. Baum, CEO
Read more →HROWHarrow Health to Announce Fourth Quarter 2019 Financial Results on March 13, 2020
NASHVILLE, Tenn., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that before the open of trading on Friday, March 13, 2020, it will release fourth quarter 2019 financial results and host a conference call at 8:30 a.m. Eastern Daylight Time /
Read more →HROWHarrow Health Publishes Third Quarter Letter to Stockholders Nashville, TN
Health Publishes Third Quarter Letter to Stockholders TN - November 13, 2019 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2019. Please click here to review Harrow Health's complementary Letter to Stockholders for the third quarter 2019. L.
Read more →HROWHarrow Health to Announce Third Quarter 2019 Financial Results on November 13, 2019
NASHVILLE, Tenn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Wednesday, November 13, 2019, it will release third quarter 2019 financial results and host a conference call at 5:00 p.m. Eastern Standard Ti
Read more →HROWHarrow Health to Attend Lake Street’s 3rd Annual Best Ideas Growth Conference September 12, 2019
NASHVILLE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 3rd Annual BIG Conference September 12, 2019. Mark L. Baum, CEO, and Andrew Boll, CFO, will be available for one-on-one meetings with investors
Read more →HROWHarrow Health Announces Second Quarter 2019 Results Consolidated quarterly revenues reach new record of $13.5 million Nashville, TN
Health Announces Second Quarter 2019 Results quarterly revenues reach new record of $13.5 million TN - August 14, 2019 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the second quarter 2019. Quarter 2019 and Other Recent Notable Highlights: 46% year-over-ye
Read more →HROWHarrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
NASHVILLE, Tenn., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule for
Read more →HROWHarrow Health Announces Launch of Mayfield Pharmaceuticals
NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate presentation for its subsidiary, Mayfield Pharmaceuticals, Inc. Mayfield is focused
Read more →HROWHarrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
NASHVILLE, Tenn., July 25, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release second quarter 2019 financial results after the close of trading on Wednesday, August 14, 2019. The company will host a conference call at 4:30 p.m. Eastern Day
Read more →HROWHarrow Health Adds Two Senior Executives to its Nashville Team
NASHVILLE, Tenn., June 25, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it has promoted Dennis Saadeh, PharmD as its Chief of Formulation Strategy and has hired Larry Dillaha, MD as its Chief Medical Officer. Dr. Saadeh, who is a 30-year veter
Read more →HROWHarrow Health, Inc to Locate Headquarters in Nashville, Tennessee
NASHVILLE, Tenn., June 18, 2019 (GLOBE NEWSWIRE) -- Tennessee Governor, Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Harrow Health, Inc (NASDAQ: HROW) announced today that the company will locate its headquarters operations in Nashville.
Read more →HROWHarrow Health Announces Renegotiated Debt Facility with SWK Holdings San Diego, CA
Health Announces Renegotiated Debt Facility with SWK Holdings Diego, CA - May 29, 2019 -- Harrow Health, Inc. (NASDAQ: HROW) today announced it has amended its loan agreement with SWK Funding LLC and its partners. SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a h
Read more →HROWHarrow Health Announces First Quarter 2019 Financial Results San Diego, CA
Health Announces First Quarter 2019 Financial Results Diego, CA - May 9, 2019 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the first quarter 2019. Quarter 2019 and Other Recent Notable Highlights: Consolidated revenue increased 39% year-over-year to a new
Read more →HROWHarrow Health to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019
SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its Chief Executive Officer, Mark L. Baum, will present an update on the company’s business at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22nd
Read more →HROWHarrow Health to Announce First Quarter 2019 Financial Results on May 9, 2019
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release first quarter 2019 financial results after the close of trading on Thursday, May 9, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight Time / 1
Read more →HROWHarrow Health Announces Fourth Quarter 2018 Financial Results San Diego, CA
Health Announces Fourth Quarter 2018 Financial Results Diego, CA - March 12, 2019 - Harrow Health, Inc. (NASDAQ: HROW) today reported results for the fourth quarter 2018. Quarter 2018 and Other Recent Notable Highlights: Revenues increased 55% year-over-year to a new record
Read more →HROWHarrow Health to Attend 31st Annual ROTH Conference on March 18, 2019
SAN DIEGO, March 04, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019 at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L. Baum, the company’s Chief Executive Officer,
Read more →HROWHarrow Health to Announce Fourth Quarter 2018 Financial Results on March 12, 2019
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced it will release fourth quarter 2018 financial results after the close of trading on Tuesday, March 12, 2019. The company will host a conference call at 4:30 p.m. Eastern Daylight Time
Read more →HROWHarrow Health Subsidiary, Mayfield Pharmaceuticals, Inc., Acquires Patented Dyspareunia Drug Candidate and Other Intellectual Property
SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced that its subsidiary, Mayfield Pharmaceuticals, Inc., has acquired drug formulation assets and intellectual property, including three recently issued patents, from Elle Pharmaceutical,
Read more →HROWHarrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary Investment will enable Melt to fund the development of its patented, non-opioid sublingual sedation and analgesia drug candidate,
Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiary will enable Melt to fund the development of its patented, non-opioid sublingual sedation and analgesia drug candidate, MELT-100 Diego, CA and Boston, MA - February 5, 2019 - Melt Pharmaceuticals
Read more →HROWImprimis Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. Harrow Health, Inc. Name Reflects the Company's Commitment to the Future of Healthcare San Diego, Calif.
Pharmaceuticals, Inc. Completes Name Change to Harrow Health, Inc. Health, Inc. Name Reflects the Company's Commitment to the Future of Healthcare Diego, Calif. - December 31, 2018 - Harrow Health, Inc. (formerly known as Imprimis Pharmaceuticals, Inc.) (NASDAQ: IMMY) announce
Read more →HROWImprimis Pharmaceuticals Announces Third Quarter 2018 Results San Diego, CA
Imprimis Pharmaceuticals Announces Third Quarter 2018 Results CA - November 13, 2018 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third Third Quarter 2018 and Other Recent Notable Revenues increased 66% year-over-year to $10.7 million Ophth
Read more →HROWEton Pharmaceuticals Announces Pricing of Initial Public Offering
Pharmaceuticals Announces Pricing of Initial Public Offering PARK, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced the pricin
Read more →HROWImprimis Pharmaceuticals Announces Second Quarter 2018 Results San Diego, CA
Imprimis Pharmaceuticals Announces Second Quarter 2018 Results CA - August 6, 2018 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter Notable Highlights from the Second Quarter Revenues of $10.4 million, up 51% year-over-year Gro
Read more →HROWEton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution PARK, Ill., July 24, 2018 -- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, announced positive top-line results for its phase III study of EM-100 ophthalmic solution. If
Read more →HROWSurface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates
Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates Diego, CA and Pleasanton, CA - May 15, 2018 - Surface Pharmaceuticals, Inc.,
Read more →HROWImprimis Pharmaceuticals Announces First Quarter 2018 Results San Diego, CA
Pharmaceuticals Announces First Quarter 2018 Results Diego, CA - May 15, 2018 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the Revenue of $8.9 million, up 45% year-over-year Gross ophthalmology-related revenue of $7.0 million, up 91%
Read more →HROWImprimis Pharmaceuticals Announces Fourth Quarter 2017 Results San Diego, CA
Pharmaceuticals Announces Fourth Quarter 2017 Results Diego, CA - March 8, 2018 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter 2017. Revenue of $7.3 million, up 27% yea
Read more →HROWImprimis Pharmaceuticals Announces Third Quarter 2017 Results San Diego, CA
Pharmaceuticals Announces Third Quarter 2017 Results Diego, CA - November 14, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the third quarter 2017. Quarter 2017 and Recent Financial H
Read more →HROWImprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results San Diego, CA
Pharmaceuticals Announces Second Quarter 2017 Financial Results Diego, CA - August 10, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the second quarter 2017. Quarter 2017 and Recent F
Read more →HROWImprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings San Diego, CA
Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings Diego, CA - July 20, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has entered into a $16 million senior secured non-dilutive term l
Read more →HROWEton Pharmaceuticals Announces $20 Million Series A Financing Proceeds to support the development of Eton's proprietary corticotropin product candidate, Peyronie's Disease product candidate and other sterile injectable p
Pharmaceuticals Announces $20 Million Series A Financing to support the development of Eton's proprietary corticotropin product candidate, Peyronie's Disease product candidate and other sterile injectable product candidates IL and San Diego, CA - June 20, 2017 - Eton Pharmaceu
Read more →HROWImprimis Pharmaceuticals Announces First Quarter 2017 Financial Results San Diego, CA
Pharmaceuticals Announces First Quarter 2017 Financial Results Diego, CA - May 10, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the first quarter 2017. First Quarter 2017 Revenue Hig
Read more →HROWImprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears Imprimis begins roll-out of dry eye disease formulary with innovative autologous serum eye drop program San Diego, Calif.
Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears begins roll-out of dry eye disease formulary with innovative autologous serum eye drop program Diego, Calif. and Seattle, Wash. - May 2, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY)
Read more →HROWImprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. Midwest Largest distributor of ophthalmic products in the Midwest to expand Imprimis' abi
Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. distributor of ophthalmic products in the Midwest to expand Imprimis' ability to serve strategic accounts and accelerate Diego, Calif. and Bloomington, Minn
Read more →HROWImprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease Formulation Expected to be a Cornerstone of Imprimis' New Dry Eye Program San Diego, Calif.
Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Expected to be a Cornerstone of Imprimis' New Dry Eye Program Diego, Calif. - April 6, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, announced today that
Read more →HROWImprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering San Diego, Calif.
Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering Diego, Calif. - March 22, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, announced today that it has entered into agreements with two accredited investors
Read more →HROWImprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results San Diego, CA
Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Diego, CA - March 21, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2016. Fou
Read more →HROWImprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility Improved efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio San Diego, Calif.
Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio Diego, Calif. - February 16, 2017 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focu
Read more →HROWImprimis Pharmaceuticals Announces $9.8 Million Private Placement of Units San Diego, Calif.
Pharmaceuticals Announces $9.8 Million Private Placement of Units Diego, Calif. - December 19, 2016 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today announced that it has entered into a definitive securities purchase agreement with various accredited investors and certain
Read more →HROWImprimis Pharmaceuticals Announces Third Quarter 2016 Financial Results San Diego, Calif.
Pharmaceuticals Announces Third Quarter 2016 Financial Results Diego, Calif. - November 14, 2016 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the production and dispensing of high quality innovative compounded medications, today reported
Read more →HROWImprimis Pharmaceuticals Announces Second Quarter 2016 Financial Results San Diego, CA
Pharmaceuticals Announces Second Quarter 2016 Financial Results Diego, CA - August 15, 2016 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding business model, today reported finan
Read more →HROWImprimis Pharmaceuticals Announces $2 Million Equipment Sale Leaseback Agreement with Essex Capital Corporation San Diego, Calif.
Imprimis Pharmaceuticals Announces $2 Million Equipment Sale Leaseback Agreement with Essex Capital Corporation San Diego, Calif. - August 11, 2016 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through it
Read more →HROWImprimis Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Business Update San Diego, CA
Pharmaceuticals Announces First Quarter 2016 Financial Results Provides Business Update Diego, CA - May 12, 2016 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company dedicated to making drugs affordable again through its Branded Compounding business model,
Read more →HROWImprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results and Provides Business Update San Diego, CA
Pharmaceuticals Announces Fourth Quarter and Year-End 2015 Results and Provides Business Update Diego, CA - March 23, 2016 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable
Read more →HROWImprimis Pharmaceuticals Announces Proposed Public Offering of Common Stock San Diego, CA
Pharmaceuticals Announces Proposed Public Offering of Common Stock Diego, CA -- March 10, 2016 -- - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), ("Imprimis" or the "company"), a pharmaceutical company focused on the development and commercialization of proprietary compounded
Read more →HROWImprimis Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2015 Financial Results Revenue growth continues in 2016 with unit sales of core ophthalmology formulations expected to double in the first quart
Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2015 Financial Results growth continues in 2016 with unit sales of core ophthalmology formulations expected to double in the first quarter of 2016 compared to the fourth quarter of 2015 Diego, CA - March 3, 20
Read more →HROWImprimis Pharmaceuticals Announces Third Quarter 2015 Financial Results and Provides Business Update Management will host conference call today at 4:30 p.m. EST (1:30 p.m. PST) San Diego, CA
Imprimis Pharmaceuticals Announces Third Quarter 2015 Financial Results and Provides Business Update Management will host conference call today at 4:30 p.m. EST (1:30 p.m. PST) San Diego, CA - November 12, 2015 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a specialty ph
Read more →HROWImprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015 San Diego, CA
Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015 San Diego, CA - October 20, 2015 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulatio
Read more →HROWImprimis Pharmaceuticals Signs License Agreement to Bring Proprietary Compounded Ophthalmic Formulations to Ophthalmologists in Canada Agreement represents the Company's first international licensing relationship San Die
Pharmaceuticals Signs License Agreement to Bring Proprietary Compounded Ophthalmic Formulations to Ophthalmologists in Canada represents the Company's first international licensing relationship Diego, CA -- August 12, 2015 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a ph
Read more →HROWImprimis Pharmaceuticals Announces First Quarter 2015 Financial Results and Provides Business Update Management will host conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) San Diego, CA
Pharmaceuticals Announces First Quarter 2015 Financial Results Provides Business Update will host conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) Diego, CA - May 13, 2015 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the developme
Read more →HROWImprimis Pharmaceuticals Announces $15 Million Term Loan Agreement with Life Sciences Alternative Funding LLC Funds to be used to accelerate the expansion and growth of the company's proprietary ophthalmology and urology
Pharmaceuticals Announces $15 Million Term Loan Agreement Life Sciences Alternative Funding LLC to be used to accelerate the expansion and growth of the company's proprietary and urology businesses Diego, CA - May 12, 2015 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a ph
Read more →HROWImprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results and Provides Business Update Patent-pending ophthalmic formulation fourth quarter 2014 revenues increased by over 101% compared to thi
Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Results and Provides Business Update ophthalmic formulation fourth quarter 2014 revenues increased by 101% compared to third quarter 2014 revenues for the same products urology launch expected to accelerate growth wi
Read more →HROWImprimis Pharmaceuticals Announces Two Key Leadership Promotions John Saharek Appointed to Chief Commercial Officer and Andrew R. Boll to Chief Financial Officer San Diego, CA
Pharmaceuticals Announces Two Key Leadership Promotions Saharek Appointed to Chief Commercial Officer and Andrew R. Boll to Chief Financial Officer Diego, CA - February 2, 2015 - Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development
Read more →HROWImprimis Pharmaceuticals Signs Agreement to Acquire PCAB-Accredited Pharmacy in California Agreement to acquire Park Compounding marks an important milestone and a significant step forward to achieving nationwide distrib
Pharmaceuticals Signs Agreement to Acquire Pharmacy in California to acquire Park Compounding marks an important milestone and a significant step forward to achieving nationwide distribution capability for Imprimis' patent-pending ophthalmic and urologic formulations Diego, C
Read more →HROWImprimis Pharmaceuticals Reports on Third Quarter 2014 Financial Results and Provides Update on Business Developments Patent-pending ophthalmic formulation revenues increased over 190% compared to the second quarter 2014
Pharmaceuticals Reports on Third Quarter 2014 Financial Results Provides Update on Business Developments ophthalmic formulation revenues increased 190% compared to the second quarter 2014 will host conference call today at 4:30 p.m. EST (1:30 p.m. PST) Diego, CA - November 1
Read more →HROWImprimis Pharmaceuticals Enters into License Agreement for Patented Urology Formulation Patented formulation of alkalized lidocaine and heparin has been prescribed as a compounded drug for individual patients in differen
Pharmaceuticals Enters into License Agreement Patented Urology Formulation Patented formulation of alkalized lidocaine and heparin has been prescribed as a compounded drug for individual patients in different dosages in thousands of insurance reimbursed bladder instillation tr
Read more →HROWImprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
aboll@imprimispharma.com Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update SAN DIEGO, August 13, 2014/PR Newswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to deliveri
Read more →HROWJen Carroll jcarroll@imprimispharma.com 858.704.4587 Imprimis Pharmaceuticals Announces Acquisition of Pharmacy Creations, Empowering Company to Make and Distribute its Patent-Pending Proprietary Formulati
Pharmaceuticals Announces Acquisition of Pharmacy Creations, Company to Make and Distribute its Patent-Pending Proprietary Formulations marks important milestone as company approaches launch targeting ophthalmologists- DIEGO, February 11, 2014/PRNewswire/ -- Imprimis Pharmace
Read more →HROWImprimis Pharmaceuticals, Inc. "A Unique Approach to 505(b)(2)" July 2013 Mark L. Baum, C.E.O. 1 Safe Harbor Statement This presentation contains "forward-looking statements" as defined in the Private Securities Litigati
Imprimis Pharmaceuticals, Inc. "A Unique Approach to 505(b)(2)" Mark L. Baum, C.E.O. Safe Harbor Statement This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forwa
Read more →HROWJosh Berg Imprimis Pharmaceuticals, Inc. (858) 704 4041 FOR IMMEDIATE RELEASE Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company Agreement is the first to emerge under
Imprimis Pharmaceuticals, Inc. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company Agreement is the first to emerge under exclusive partnership between Imprimis Pharmaceuticals and Professional Compounding Centers of America (PCCA); ac
Read more →HROWExecutive Summary Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) Who We Are Imprimis Pharmaceuticals, Inc. (Imprimis) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulat
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) Imprimis Pharmaceuticals, Inc. (Imprimis) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Imprimis expects to use its proprietary Accudel drug delivery technologies, propri
Read more →HROWMark L. Baum Imprimis Pharmaceuticals, Inc. (858) 433-2800 FOR IMMEDIATE RELEASE Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock Closing of Offering Expected
Contact: Mark L. Baum Imprimis Pharmaceuticals, Inc. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock Closing of Offering Expected February 13, 2013 SOLANA BEACH, Calif., February 7, 2013/PRNewswire/ -- Imprimis Pharmaceutical
Read more →HROWIMPRIMIS PHARMACEUTICALS CLOSES $7.95M FINANCING AND PROVIDES PROGRESS REPORT TO SHAREHOLDERS Solana Beach, CA.
IMPRIMIS PHARMACEUTICALS CLOSES $7.95M FINANCING AND PROVIDES PROGRESS REPORT TO SHAREHOLDERS Solana Beach, CA. April 27, 2012 - Imprimis Pharmaceuticals, Inc. (OTC Markets: IMMY) announced that it has closed a $7.95M private placement of stock and warrants and is providing an u
Read more →HROWTransdel Pharmaceuticals Reports Third Quarter and Year-to-Date 2010 Results
Transdel Pharmaceuticals Reports Third Quarter and Year-to-Date 2010 Results LA JOLLA, CA November 8, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal d
Read more →HROWTransdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer LA JOLLA, CA October 21, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary tran
Read more →HROWTransdel Pharmaceuticals Reports Second Quarter and Year-to-Date 2010 Results
Transdel Pharmaceuticals Reports Second Quarter and Year-to-Date 2010 Results LA JOLLA, CA August 12, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal d
Read more →HROWTransdel Pharmaceuticals, Inc. June 2010 Safe Harbor Statement The Company cautions you that the statements included in this presentation that are not a description of historical facts are forward-looking statements. The
Product launched in April 2010. Double digit growth estimated in 2010 for Flector and Voltaren Gel Cosmeceuticals TDLP310 Lead product - anti-cellulite formulation License agreement with JH Direct, LLC Anticipate launch in second half of 2010 License agreement with Jan Marini Ski
Read more →HROWTransdel Pharmaceuticals Reports First Quarter 2010 Results
Transdel Pharmaceuticals Reports First Quarter 2010 Results LA JOLLA, CA May 13, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, toda
Read more →HROWTransdel Pharmaceuticals Closes $1 Million Debt Financing Company Provides Update on Recent Accomplishments
Transdel Pharmaceuticals Closes $1 Million Debt Financing Company Provides Update on Recent Accomplishments LA JOLLA, CA April 8, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using i
Read more →HROWTransdel Pharmaceuticals Announces Management Reorganization
Transdel Pharmaceuticals Announces Management Reorganization LA JOLLA, CA February 18, 2010 Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platfor
Read more →HROWTransdel Pharmaceuticals, Inc. Symbol: TDLP.OB October 2009 2 Safe Harbor Statement The Company cautions you that the statements included in this presentation that are not a description of historical facts are forward-lo
JH Direct partnership for anti-cellulite product) Highly qualified team with significant industry experience 23 Contact Us Transdel Pharmaceuticals, Inc. (OTC BB: TDLP.OB) 4225 Executive Square Suite 485 La Jolla, CA 92037 Corporate Headquarters Investor Contact John Lomoro Chief
Read more →HROWTransdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel Primary Efficacy Endpoint Met Excellent Safety and Tolerability Profile Demonstrated Minimal Systemic
Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel Primary Efficacy Endpoint Met Excellent Safety and Tolerability Profile Demonstrated Minimal Systemic Exposure Found in Pharmacokinetic Sub-Study Company to Hos
Read more →HROWTransdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors Sports, Business,
Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Broadcaster, and Former Chairman of the President's Council on Physical Fitness and Sports, to Board of Directors Business, Media, and Community Leader To Contribute To Specialty Pharma's Corporate Gover
Read more →HROWDATED JUNE 16, 2008 Contact: John Lomoro Chief Financial Officer Transdel Pharmaceuticals, Inc. 858-457-5300 Transdel Initiates Ketotransdel Phase 3 Clinical Program for Pain Cato Research Signed as Strateg
Pharmaceuticals, Inc. Initiates Ketotransdel 3 Clinical Program for Pain Research Signed as Strategic Partner for the Phase 3 Program CA - June 16, 2008 -- Transdel Pharmaceuticals, Inc. (OTCBB: TDLP), a specialty pharmaceutical company developing non-invasive, topically adm
Read more →HROWDATED MAY 15, 2008 Contact: John Lomoro Chief Financial Officer Transdel Pharmaceuticals, Inc. 858-457-5300 Transdel Pharmaceuticals Closes $4 Million Financing Proceeds Will Support Phase 3 Lead Clinical P
Pharmaceuticals, Inc. Pharmaceuticals Closes $4 Million Financing Will Support Phase 3 Lead Clinical Pain Program for CA - May 15, 2008 -- Transdel Pharmaceuticals, Inc. (OTC BB:TDLP), a specialty pharmaceutical company focused on the development and commercialization of non
Read more →HROWUnassociated Document Contact: John Lomoro Chief Financial Officer Transdel Pharmaceuticals, Inc. 858-457-5300 Transdel Pharmaceuticals Appoints Chief Medical Officer and Chief Operating Officer LA JOLLA, C
Pharmaceuticals, Inc. Pharmaceuticals Appoints Chief Medical Officer and Chief Operating Calif., April 24 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC specialty pharmaceutical company focused on the development and commercialization of non-invasive topically
Read more →HROWTransdel Pharmaceuticals Appoints Mr. Anthony S. Thornley to Its Board of Directors LA JOLLA, CA
Pharmaceuticals Appoints Mr. Anthony S. Thornley to Its Board of CA -- Nov 6, 2007 -- Transdel Pharmaceuticals, Inc. (OTC BB:TDLP.OB), specialty pharmaceutical company focused on the development and commercialization of non-invasive topically targeted medications, today annou
Read more →HROWTRANS-PHARMA CORPORATION (A DEVELOPMENT STAGE COMPANY) FINANCIAL STATEMENTS For The Years Ended
DEVELOPMENT STAGE COMPANY) The Years Ended December 31, 2006 and 2005 and The Period From July 24, 1998 (Inception) Through December 31, OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM DEVELOPMENT STAGE COMPANY) Report of Independent Registered Public Accounting Firm 1 F
Read more →HROWHarrowing Honeymoon -- Gay Couple's Romantic Destination Turns Deadly in Second Book of Mystery Series
EAST HARTFORD, Conn., February 9, 2005 (PRIMEZONE) -- With a traumatic year behind them, Barnaby Moss and Arnie Kotkin have only one thing on their minds: a quiet trip to Vermont to seal their union and steal a little relaxation. Fate has different plans, however. Murder Junction
Read more →Competitive Position
How HROW ranks across every disease it competes inCompetitive Position is a premium feature
See how HROW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial